Focused On-demand Library for tRNA-dihydrouridine(16/17) synthase [NAD(P)(+)]-like

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q6P1R4

UPID:

DUS1L_HUMAN

Alternative names:

tRNA-dihydrouridine synthase 1-like

Alternative UPACC:

Q6P1R4; A6NHV4; Q96AI3

Background:

The tRNA-dihydrouridine synthase 1-like protein, encoded by the gene with the UniProt accession number Q6P1R4, plays a crucial role in the post-transcriptional modification of tRNA. It catalyzes the synthesis of dihydrouridine, a modified base found in the D-loop of most tRNAs. This modification is essential for the proper folding and structural dynamics of tRNA, impacting its stability and function in protein synthesis.

Therapeutic significance:

Understanding the role of tRNA-dihydrouridine synthase 1-like could open doors to potential therapeutic strategies. Its involvement in the fundamental process of protein synthesis positions it as a potential target for interventions in diseases where protein synthesis regulation is disrupted.